期刊
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
卷 1867, 期 8, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.bbadis.2021.166148
关键词
Type 2 diabetes mellitus; Cardiovascular risk; Oxidative stress; Inflammation; Glycation; Novel biomarkers
资金
- Eli Lilly
- MSD
- Novo Nordisk
- Novartis
- Sanofi-Aventis
- AstraZeneca
- Boehringer Ingelheim
- Coca-Cola
- Medtronic
- Merck
- Roche Diagnostics
- Sanofi
- TrigoCare International
- Pfizer
- Amgen
- Kowa
- Meda
- Mylan
- Merck Sharp Dohme
- Servier
Diabetes is a major risk factor for cardiovascular disease, with high blood glucose leading to increased reactive oxygen species and affecting endothelial function and atherosclerotic plaque formation. Biomarkers play a crucial role in screening, prediction, diagnosis, and monitoring of cardiovascular risks associated with diabetes.
Diabetes represents the leading risk factor for the development of cardiovascular disease (CVD). Chronic hyperglycemia and/or acute post-prandial changes in blood glucose determine an increase in reactive oxygen species (ROS), which play a fundamental role in endothelial dysfunction and in the nuclear transport of proatherogenic transcription factors that activate the inflammasome. In addition, the glycemic alteration favors the formation and stabilization of atherosclerotic plaque through the mechanism of non-enzymatic glycation of different molecules, with the establishment of the so-called advanced glycosylation end products (AGE). Laboratory information provided by the level of biomarkers could make a quantitative and qualitative contribution to the clinical process of screening, prediction, prevention, diagnosis, prognosis and monitoring of cardiovascular (CV) risk linked to diabetes. This review describes the importance of specific biomarkers, with particular focus on novel ones, for stratifying and management of diabetes CV risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据